The next time Stephen Quake is prescribed a drug, he says he won't worry about having a bad reaction. The Stanford University professor will simply consult his genome to see if there are any warning signs in his DNA.
Illumina, Inc. announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs.
Almac will be attending BIO 2010, the annual Bio Industry Association convention, at which it will announce the extension of its unique site specific PEGylation technology to cover single domain antibody fragments.
Thanks to an interdisciplinary team of researchers, scientists now have a more complete understanding of one of the human body’s most vital structures: the red blood cell.
The density of transposable (jumping) elements between sex chromosomes in primates may have important consequences for the studies of human genetic diseases, say Penn State University researchers.
EyeGate Pharma announces that they have established a research collaboration with GlaxoSmithKline (GSK) to evaluate the delivery of several GSK therapies using the EyeGate II delivery system.
Pharmacy benefits manager Medco Health Solutions Inc. said its profit grew 10 percent in the first quarter as it started doing business with several large new clients.
TxCell SA announced positive preliminary results from the ongoing Phase 1/2a clinical trial regarding OvaSave, an investigational new drug, in patients with severe and refractory Crohn’s disease.
People with a common, obesity-related liver disease that has no known treatment got a surprising benefit from vitamin E pills, researchers reported.
Sanofi-Aventis reported an 8.6 percent increase in first quarter net profit thanks to its swine flu vaccine and strong sales of diabetes treatment Lantus.
Anglo-Swiss pharmaceutical company AstraZeneca PLC reported that first-quarter profit rose by 29 percent, but cautioned that comparisons will be tougher in the second half of the year when a key patent expires.
endpoint Clinical announced that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of clinical trials.
Citeline’s TrialTrove, a leading global pharmaceutical intelligence service, now tracks more than 100,000 clinical trials around the world, making it among the most comprehensive source of clinical trial information available.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, announced the launch of Centralized Cardiac Safety 2.0, a portfolio of new solutions that enable a significant new approach to cardiac safety in clinical trials.